Vandetanib
- 申請商
- 賽諾菲股份有限公司
- 適應症
- 無法進行手術切除的局部侵犯或轉移性甲狀腺髓質癌,並且為症狀性及疾病侵襲性的患者(aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease)
- 含量
- 300MG
- 申請商
- 賽諾菲股份有限公司
- 適應症
- 無法進行手術切除的局部侵犯或轉移性甲狀腺髓質癌,並且為症狀性及疾病侵襲性的患者(aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease)
- 含量
- 100MG